Literature DB >> 29517622

PharmGKB summary: clobazam pathway, pharmacokinetics.

Rachel Huddart1, J Steven Leeder2, Russ B Altman3,4, Teri E Klein1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29517622      PMCID： PMC5914180          DOI： 10.1097/FPC.0000000000000327

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  65 in total

1.  Toxic epidermal necrolysis triggered by clobazam: a case report in a 13-year-old girl.

Authors:  Chuong D Dang; Linda Beets-Shay; Estelle C Kahn
Journal:  Pediatr Dermatol       Date:  2015-02-18       Impact factor: 1.588

2.  Pharmacokinetics of single and multiple doses of clobazam in humans.

Authors:  W Rupp; M Badian; O Christ; P Hajdú; R D Kulkarni; K Taeuber; M Uihlein; R Bender; O Vanderbeke
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

3.  Simultaneous determination of clobazam and its major metabolite in human plasma by a rapid HPLC method.

Authors:  Mohammadreza Rouini; Yalda H Ardakani; Lida Hakemi; Maryam Mokhberi; Gheise Badri
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-09-05       Impact factor: 3.205

4.  Interactions between modulators of the GABA(A) receptor: Stiripentol and benzodiazepines.

Authors:  Janet L Fisher
Journal:  Eur J Pharmacol       Date:  2011-01-14       Impact factor: 4.432

5.  A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy.

Authors:  Mark Naccarato; Deborah Yoong; Colin Kovacs; Kevin Gough
Journal:  Antivir Ther       Date:  2011-11-04

6.  An integrative population pharmacokinetics approach to the characterization of the effect of hepatic impairment on clobazam pharmacokinetics.

Authors:  Dwain Tolbert; Ihor Bekersky; Hui-May Chu; Ene I Ette
Journal:  J Clin Pharmacol       Date:  2015-09-07       Impact factor: 3.126

7.  Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy.

Authors:  Sachiyo Hashi; Ikuko Yano; Mai Shibata; Satohiro Masuda; Masako Kinoshita; Riki Matsumoto; Akio Ikeda; Ryosuke Takahashi; Kazuo Matsubara
Journal:  Eur J Clin Pharmacol       Date:  2014-10-18       Impact factor: 2.953

8.  Functional comparison of the role of gamma subunits in recombinant human gamma-aminobutyric acidA/benzodiazepine receptors.

Authors:  K A Wafford; C J Bain; P J Whiting; J A Kemp
Journal:  Mol Pharmacol       Date:  1993-08       Impact factor: 4.436

9.  Drug-metabolism mechanism: Knowledge-based population pharmacokinetic approach for characterizing clobazam drug-drug interactions.

Authors:  Dwain Tolbert; Ihor Bekersky; Hui-May Chu; Ene I Ette
Journal:  J Clin Pharmacol       Date:  2015-09-29       Impact factor: 3.126

10.  Comparison and predictors of rash associated with 15 antiepileptic drugs.

Authors:  H Arif; R Buchsbaum; D Weintraub; S Koyfman; C Salas-Humara; C W Bazil; S R Resor; L J Hirsch
Journal:  Neurology       Date:  2007-05-15       Impact factor: 9.910
View more
  4 in total

Review 1.  The Essential Medicinal Chemistry of Cannabidiol (CBD).

Authors:  Kathryn M Nelson; Jonathan Bisson; Gurpreet Singh; James G Graham; Shao-Nong Chen; J Brent Friesen; Jayme L Dahlin; Matthias Niemitz; Michael A Walters; Guido F Pauli
Journal:  J Med Chem       Date:  2020-09-10       Impact factor: 7.446

Review 2.  Pharmacogenomic Biomarkers and Their Applications in Psychiatry.

Authors:  Heejin Kam; Hotcherl Jeong
Journal:  Genes (Basel)       Date:  2020-11-30       Impact factor: 4.096

Review 3.  Super-Refractory Status Epilepticus: Prognosis and Recent Advances in Management.

Authors:  Batool F Kirmani; Katherine Au; Lena Ayari; Marita John; Padmashri Shetty; Robert J Delorenzo
Journal:  Aging Dis       Date:  2021-07-01       Impact factor: 6.745

4.  Safety and Molecular-Toxicological Implications of Cannabidiol-Rich Cannabis Extract and Methylsulfonylmethane Co-Administration.

Authors:  Kristy R Kutanzi; Laura E Ewing; Charles M Skinner; Charles M Quick; Stefanie Kennon-McGill; Mitchell R McGill; Larry A Walker; Mahmoud A ElSohly; Bill J Gurley; Igor Koturbash
Journal:  Int J Mol Sci       Date:  2020-10-21       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.